Cancer Advisor

Edited and Updated: June 2026  Caution to the Reader: This is a complex, evolving topic rooted in molecular biology and evolutionary dynamics. The material below has been distilled for clinical accessibility while preserving strict mechanistic accuracy. Key conceptual frameworks from the Care Oncology Clinic (COC) protocol and Thomas Seyfried’s press–pulse model are integrated throughout. Introduction Clinicians utilizing a metabolic framework often combine 4–5 repurposed prescription agents with 4–5 nutraceuticals. While this approach frequently yields 1–2 years of sustained, stable response, acquired resistance can emerge rapidly, turning stable disease into aggressive progression. When this occurs, critical clinical questions arise: How should the regimen be modified? Should mechanistically similar agents be cycled more frequently? Should dosing be intermittent rather than continuous? What ...

PD-1 and PD-L1 checkpoint inhibitors can produce remarkably durable responses in some patients. However, resistance remains one of the central challenges in modern oncology. A tumor may never respond to immunotherapy in the first place, or it may respond initially and later progress. The reason is important: blocking PD-1 or PD-L1 removes one immune-suppressive signal, but it does not guarantee that the immune system can recognize, enter, survive within, and destroy every cancer cell. This article explains the major biological mechanisms behind primary and acquired immunotherapy resistance , why PD-L1 alone cannot reliably predict response, how tumor evolution and the tumor microenvironment contribute to treatment failure, and what strategies researchers and oncologists are investigating to overcome resistance. Bottom line: PD-1/PD-L1 resistance is not a single disease mechanism. It is a systems problem involving tumor genetics, antigen presentation, T-cell function...

Metabolic Oncology • Tumor Microenvironment • Repurposed Medicine Cancer is not simply a mass of malignant cells. In some tumors—especially pancreatic ductal adenocarcinoma—the cancer grows inside a dense, fibroinflammatory ecosystem that can influence blood flow, drug delivery, immune activity and treatment resistance. This article examines whether repurposed drugs and selected supplements could help remodel rather than simply destroy this protective tumor microenvironment. Desmoplasia Cancer-associated fibroblasts Tumor microenvironment Pancreatic cancer Repurposed drugs Vitamin D Important: This is an educational review of cancer biology and emerging research. Repurposed drugs and supplements discussed here should not be considered established cancer treatments or substitutes for evidence-based oncology. Some are prescription medicines, may have important interactions or toxicities, and should only be considered with a...